



The Research Institute of St. Joe's Hamilton

So, what if I have some missing data or patients in my clinical trial: what's the big deal, and wouldn't imputation solve the problem?

Lehana Thabane

Disclosure and COI

· No financial COI to declare




 As a professor, I get academic credit by giving presentations like this

I recently presented a version of this talk at the meeting on Hot Topics in Neonatology in Washington DC in 2022



Barbara Schmidt and Haresh Kirpalani





In-Person Attendees:

Missing Outcome Data in Recent Perinatal and Neonatal Clinical Trials

Surser S. PAS, MARS¹⁷⁸ Regard to Mile." Joseph Prans, Mile." Sens S. De Marro, MS, MICS." Goog Mars, MIC." Lawrence Mousglass, MS, PAS, "Mile Sensors Science, MS, MSc." neven Argulani, SM, MSc." Lawrence Passars, PAS

Missing outcome data in dissigal totals may propurate the validity of the total retults and inferences for clinical practice. Although side and proterm newborns are treated as a captive patient population during their stay in the NICIs, their longterm outcomes are often assertained after discharge. This greatly increases the risk of attrition. We surveyed recessly published perioatal and necessal randomited trials in 7 high-impact general medical and pediatric journals to review the handling of missing primary outcome data and any choice of imputation methods. Of 87 eligible totals in this survey, 77 (89%) had incomplete primary outcome data. The missing extrome data were not discussed at all in 9 reports (12%). Most study teams restricted their main analysis to participants with complete information for the primary outcome (61 trials; 79%). Only 38 of the 77 teams (49%) performed sensitivity analyses using a variety of imputation methods. We conclude that the handling of missing primary outcome data was frequently inadequate in recent randomized perinatal and measural trials. To improve future approaches to missing extrorre data, we discuss the strengths and limitations of different impatation methods, the appropriate estimation of sample size, and how to deal with data withdrawial However, the best strategy to reduce bias from mining outcome data in perinatal and monatal trials remains prevention, investigators should antidpate and preempt missing data through careful study design, and closely monitor all incoming primary outcome data for completeness during the conduct of the

Missing switcome data in randomized controlled trials (RCTs) may isopardize the comparability between the comparison groups and companies informace about treatment effects. Missing data may artso in many ways in portional and neountal trials. In the birth heaptist or NGCs parents or guardians of participating infants may not respond to questions, ful to adhere to trial protocols, request with drawel from protocols wayly, or relates congaing data collection. Although caragivers can easily assess in-hospital encourse for sick and preserve newborn infants admitted to the ICDs, their important longer-term continency require accertainment later in childhood and increases the risk of attrition, for example, nearly 40% of the primary subtome data were missing at age 5 years in a revent high-profile trial comparing greenal amedients with awake regional amethesia for infants undergoing lemma regions?

Despite the large literature on prevention and handling of mining data, hit reporting and desling with mining data remain inadequate in chinical trials. We in plausitist that perinatel and mountail trials are not exceptions. We surveyed recently published perinatel and secondal RCTs in high-impact general medical and pediatric journals to review the handling of mining primary outsine data and use of impactation methods, we despite the perinate and impactation methods, and

Satract



Torse to Direct (internally engineerings and Suffer Specification Source to Detect Dispersion Intelligent Sensites (Species States) Sensity Sacrat Afficial analysis of Charles Statement & Charles & Charl Department of Perlations, Meximum School of Minister. Interior of Wingstown, Philosophy Remarkage Separate of February Sampley Separatives of Consent Record & CopingStery (Note: Sentence and Record provinced of cought from an installability Throughouts Propietros attatigator Canorina Springers Distores Grants Cierce for Concignment of that Waykon et more Novel districtments brivel fathering. Destinations, Thereign of Despertusings and Section 1. Department of Golde Health, Districtional Disserving Days Start, Start Street, Triangles Professor Parliation of streets Pengagong Windpieres Ne Seventus Pottoson Roberts shakkett inventily invelors Intelligence on Town to Automotive interesting light free

This is not likely exhibits by outside Jung summerly and and draggest this meanure, acquired 300, 1911 additional conjunct, exhibits the manuscript and distance of a solid reason being the bringing to the final figures, and with a plant of the plants; the bringing to the plants of the plants of

Microsoftware 14 percent of the

Accessed for supplication than 5, 2007.

Approxis germanisms to grade Trabure (mi) Signamust of local Sciences Methods, Sciences, and Impact, Wallacter Crannelly, Johne Sacc Studiese Security Science, M. Sciences (middlesser special activities Signature Amilian) Language (M. Sarpero (M. All) Language (M. Sarpero) (M. Sarpero (M. All) Language (M. Sarpero) (M. Sarpero (M. All)

ROUNCE COR NAMED FOR BUY AND DOCUMENTS

Depriet G 201 laying direction discount of the district

PERSONAL PROPERTY AND PARTY.

CONTROL OF THE PARTY IN COLUMN 2. THE ACCUSATION ASSESSMENT THE PARTY THE PARTY TO SECURE THE PARTY TO SECURE THE PARTY TO SECURE THE PARTY THE PA

Speller (14, 16.1) Planty Cottol Waving Systems Sales in Secret Fernation and Secretar Directal Stress Federical SIGN (SSS) 409(SSS) (III

Making the Most of Missing Data

From Clication, INC, MAC^{*} and Saction C. Dreemberg, MC, MC, MC, MC^{*}

Cinical trials are domainfling, resource terminies, and essential to the health and well-feeting of childrens, in this issue of features, Li and collapses, *estimate the magnitude of an others-overhooked problem within momental and perinatal children triple. Their results domainstrate that missing primary maximum data are often ignored or mishamfled, which developes statistical power, increases historical process. Increases that, and may proposition the validity of clinical trial results. The authors previole practical approaches to result mixing votecome data through clinical trial design strategies and review covering analyses; and importation methods to miligate the risk of line. The problem of missing data is not unique to the normal and perinatal genephalation,* and is interested in trials deviced on pediatric clossics medical conditions, including SITs,* obserty, 5° and sethers.* Thus, the concepts reviewed by Li and collapses apple brandle.

Lit and colleagues methos been efficient researchers and discident should be expetation of the potential for mining outcome data and take super to relating this rela-These efficient most man during the design stages before the clinical trial begins, when relatinishes should be treeded early to consider how attestion may affect sample size considerations and to identify sensitivity analyses best valued for the relatinishes as a sensitive as massive as alternative standardings, makes a deconsileated dispositive of a conference on massive as alternative standardings, makes a deconsileated dispositive of a conference on participant families. Decisionalized clinical trials are technology, home health providers, and local clinics in data softening to residue gaugaphic, thus, and travel related families for participant families and may improve participant technology. Direct to-density trials are similar, but also forter the role of powers and carrigions in suggesting clinical research activities. During the trial, it is november of researchers to reagap porticipates and their femilies, whereas minintagin lawders and manintagin trial-related benefits. After the total, disating results with families beign maintain the relation to the only expense or without for incidence that the trial.

Superiting guidelines, each as the Consolidated Standards of Reporting Tradachtement, may benefit from indesting mining naturance data reporting standards. ¹⁸ Wednick journals, should livest as port of the review process that mining standards data he reported and that best practice sensitivity analyses are used to inform the suscerulary that results from mining data. Checiaus next be excelled to the form the data for the standard of the standard process of the standard of the standard of mining autrems data when evolunting clinical trials and interporting knowledge guised flows such trials into discuss parties. However, it is necessary to take a numeral view toward mining data. Indeed, some clinical trials with relatively largesensation of noting outcome data here had a substantial impact on chancel grants. Consistent of Valuation, Edit (Inventor) School of the state, St

In the story and threshing makes the equipment and and the seal of entirely for important inflammad amount, and such sufficient part and the flags recognition or all control and agree to be assumed to the extraction of the seal.

Annual transport of the Annual States of the Annual

American appearance in Sept. 1 (1994) of the Sept. Note that the Sept. 1 (1994) of the S

KOMMUNICH KANSAN PARK MIT AND IS

Somethia.

NAME OF STREET STREET

THE PERSON NAMED IN COLUMN TO SECURE THE PERSON NAMED IN COLUMN THE PERSON

SHARES MAKE A conservation for other solver facility and the executable compression of the property and the con-

Budle Claimant, Greening St. Many he Manufacturing Data. Receives 2004/05/5 electrodes

THE RESERVE AND ADDRESS OF THE PERSON NAMED IN COLUMN TWO IN COLUMN TO THE PERSON NAMED IN COLUMN TWO IN COLUMN TW

PERSONAL VALUE (EL CURSO) I MARCO TOTAL ESTABLISTO.

THE TRANSPORT AND PRODUCTION OF THE PERSONAL PROPERTY OF THE PERSONA

COMMENTARY

How prevalent is problem of missing data in perinatal and neonatal trials?

- We searched Medline (via PubMed) for RCTs that enrolled newborns or their birthing parents, reported outcomes n the children
- ☐ Trials published between January 1, 2020, and December 31, 2022.
- ☐ Sources:
 - ✓ <u>High-impact general medical journals</u>: Lancet, NEJM, JAMA, BMJ



✓ <u>Pediatric specialty journals</u>: JAMA Pediatrics, Pediatrics, Lancet Child and Adolescent Health.

Setting the stage

- ■We are talking about <u>missing outcome data</u> in a trial
 - ✓ Part or all outcome data for some patients
 - √ These are not missing by design



- ■We are <u>NOT</u> talking about <u>missing</u> demographic or prognostic data
- ☐ This assumes that we have information on some or all baseline characteristics



Practice of Handling Missing Outcome Data	Total Number of RCTs (N = 77), No. (%)	RCTs in Pediatric Journals (N = 35), No. (%)	RCTs in General Journals (N = 42), No. (%)	P
Not reporting missing data in the results	9 (12)	7 (20)	2 (5)	.07 ^d
Primary approach for intervention	on effect estimates	50		0
Complete-case analysis	61 (79)	23 (66)	38 (91)	<.01 ^d
Best-case scenario	1 (1)	0	1 (2)	
Unclear	15 (20)	12 (34)	3 (7)	
Sensitivity analysis performed for	or intervention effect estimates			
Yes	38 (49)	10 (29)	28 (67)	<.01 ^e
No	39 (51)	25 (71)	14 (33)	
Imputation methods used in 38	RCTs with sensitivity analysis ^a	101100000000000000000000000000000000000		-
Single imputation ^b	15 (40)	2 (20)	13 (46)	.26 ^d
Multiple imputation	22 (58)	4 (40)	18 (64)	.27 ^d
Inverse probability weighting method	3 (8)	2 (20)	1 (4)	.16 ^d
Model-based imputation ^c	2 (5)	0	2 (7)	-
Unclear	3 (8)	2 (20)	1 (4)	.16 ^d
Sensitivity analysis yields differe	ent results from primary approach	10		
Yes	1 (3)	0	1 (4)	.74 ^d
No	31 (81)	8 (80)	23 (82)	
Unclear	6 (16)	2 (20)	4 (14)	

⁶ The following model-based imputation methods were used: Linear mixed-effects model and pattern-mixture model (1 RCT or 50% for each method).

Calculated from Fisher's exact test.

" Calculated from x2 test.

TABLE 1 Practice of Handling Missing Primary Outcome Data in 77 Perinatal and Neonatal RCTs Published Between 2020 and 2022 in 7 High-Profile

What did we find?

- □Included 87 eligible perinatal and neonatal RCTs
- □77/87 (89%) trials had missing primary outcome data
- □61 (79%) used a <u>complete-case analysis</u> as their primary approach



□38 (49%) trial reports included some sensitivity analysis using a variety of imputation methods





□There is high prevalence of missing data in recent perinatal and neonatal trials
□The handling of missing primary outcome data has been largely inadequate in recent perinatal and neonatal trials

Unfortunately, perinatal and neonatal area is not the only clinical area challenged by these deficiencies




This talk was about imputation of missing data in trials: What you need to know about what imputation is, why it is necessary, what the current practice looks like, what the best



methods to impute are, what it cannot do, and how to prevent the need for it





What is imputation of missing data?

What does imputation mean?



"The practice of filling in missing data with plausible values."

(Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3–15)

In general, imputation methods fall under 4 main categories

- Single imputation methods: replacing missing data with single plausible value
 - ✓ Mean/median imputation
 - ✓ Last observation carried forward/backward
 - ✓ Worst/best case scenario
 - ✓ Prediction of missing data



- Multiple imputation methods: replacing missing data with multiple plausible values
- Model-based imputation methods
 - ✓ Likelihood based methods
 - ✓ Mixture models
 - ✓ Monte Carlo Markov Chain (MCMC)
 - ✓ EM algorithm
 - ✓ AI methods
- Weighting methods
 - ✓ Inverse probability weighting



Complete Case Analysis

Time 1: no missing data

_Time 2: with missing data



Analysis Result Using Complete Cases




Single Imputation Analysis

Time 1: no missing data



Time 2: with missing data



Analysis based on imputed dataset



Adhoc: Single Imputation Analysis



Time 1: no missing data



Time 2: with missing data



Multiple Imputation Analysis







The steps for model-based imputation

- 1. Use ML (maximum likelihood) to estimate parameters based on complete data
- 2. Use ML to impute missing data based on estimated parameters in Step 1
- 3. Re-do step 1 based on imputed dataset



4. Repeat Steps 1-3 until no changes in parameter estimates Inverse Probability Weighting Method

- <u>Inverse probability weighting</u> in conjunction with regression modeling
- Also commonly referred to as
 - √ weighted complete-case analysis
 - √ inverse probability of participation/attrition weighting



- □ The IPW is based on the assumption that individual information that <u>can predict the probability of inclusion (non-missingness)</u> <u>are available</u>
- ☐ The procedure is done in the following steps:
 - 1. Calculate the <u>probability of non-missing information PS(X)</u> using a logistic regression model—the response is the nonmissingness and the covariates are its possible predictors.
 - 2. The weight of each subject is given by the inverse of the predicted probability (ie. weight = 1/PS(X))

3. Then the analysis is performed using a weighted regression model


Inverse PSW Method



Probability score
$$PS(X) = 0.10$$

IPW=
$$1 = 10$$







IPW is used to <u>inflate</u> the weight for participants who



are under-represented due to missing data from similar participants





☐ There are <u>several methods</u> for dealing with missing data



□ All can be classified under 4 classes: <u>single</u>, <u>multiple</u>, <u>model-based</u> imputation and <u>weighting</u>





Why do we need imputation for missing data?

In general, missing data create many problems including

- ☐ Increase the risk of bias
- ☐ Decrease <u>statistical power</u>
- □ Reduce the <u>representativeness</u> of the sample



- □ Negatively impact the
 - ✓ <u>applicability</u> of results
 - ✓ reliability of results
 - ✓ interpretability of results
 - ✓ <u>validity</u> of the statistical methods (at least in trials)



So, imputation for missing data is a <u>viable solution</u> to these problems!



In practice, evaluation of the quality or certainty evidence from published study reports require that



we assess the risk of bias in the evidence The Cochrane Risk of Bias Tool



2 (RoB 2) and the ROBINS-1 for assessment of risk in observational studies tool partly



require evaluation of the risk of bias due to missing data



1. bias arising from the randomization process:





- 2. bias due to deviations from intended interventions;
- 3. bias due to missing outcome data;
- 4. bias in measurement of the outcome; and
- 5. bias in selection of the reported result.



RESEARCH METHODS AND REPORTING



ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions



Jonathan AC Sterne,¹ Miguel A Hernán,² Barnaby C Reeves,³ Jelena Savović,^{1,4} Nancy D Berkman,⁵ Meera Viswanathan,⁶ David Henry,⁷ Douglas G Altman,⁸ Mohammed T Ansari,⁹ Isabelle Boutron,¹⁰ James R Carpenter,¹¹ An-Wen Chan,¹² Rachel Churchill,¹³ Jonathan J Deeks,¹⁴ Asbjørn Hróbjartsson,¹⁵ Jamie Kirkham,¹⁶ Peter Jüni,¹⁷ Yoon K Loke,¹⁸ Theresa D Pigott,¹⁹ Craig R Ramsay,²⁰ Deborah Regidor,²¹ Hannah R Rothstein,²² Lakhbir Sandhu,²³ Pasqualina L Santaguida,²⁴ Holger J Schünemann,²⁵ Beverly Shea,²⁶ Ian Shrier,²⁷ Peter Tugwell,²⁸ Lucy Turner,²⁹ Jeffrey C Valentine,³⁰ Hugh Waddington,³¹ Elizabeth Waters,³² George A Wells,³³ Penny F Whiting,³⁴ Julian PT Higgins³⁵



Table 1 Bias domains	included in ROBINS-I	
Domain	Explanation	
Pre-intervention	Risk of bias assessment is mainly distinct from assessments of randomised trials	
Bias due to confounding	Baseline confounding occurs when one or more prognostic variables (factors that predict the outcome of interest) also predicts the intervention received at baseline ROBINS-I can also address time-varying confounding, which occurs when individuals switch between the interventions being compared and when post-baseline prognostic factors affect the intervention received after baseline	
Bias in selection of participants into the study	When exclusion of some eligible participants, or the initial follow-up time of some participants, or some outcome events is related to both intervention and outcome, there will be an association between interventions and outcome even if the effects of the interventions are identical. This form of selection bias is distinct from confounding—A specific example is bias due to the inclusion of prevalent users, rather than new users, of an intervention	
At intervention	Risk of bias assessment is mainly distinct from assessments of randomised trials	
Bias in classification of interventions	Bias introduced by either differential or non-differential misclassification of intervention status Non-differential misclassification is unrelated to the outcome and will usually bias the estimated effect of intervention towards the null Differential misclassification occurs when misclassification of intervention status is related to the outcome or the risk of the outcome, and is lik lead to bias	
Post-intervention	Risk of bias assessment has substantial overlap with assessments of randomised trials	
Bias due to deviations from intended interventions	Bias that arises when there are systematic differences between experimental intervention and comparator groups in the care provided, which represent a deviation from the intended intervention(s) Assessment of bias in this domain will depend on the type of effect of interest (either the effect of assignment to intervention)	
Bias due to missing data	Bias that arises when later follow-up is missing for individuals initially included and followed (such as differential loss to follow-up that is affected by prognostic factors); bias due to exclusion of individuals with missing information about intervention status or other variables such as confounders	
Bias in measurement of outcomes	Bias introduced by either differential or non-differential errors in measurement of outcome data. Such bias can arise when outcome assessors are aware of intervention status, if different methods are used to assess outcomes in different intervention groups, or if measurement errors are related to intervention status or effects	
Bias in selection of the reported result	Selective reporting of results in a way that depends on the findings and prevents the estimate from being included in a meta-analysis (or other synthesis)	

Therefore, it is required in the overall evaluation of the certainty of evidence through GRADE





As a result...

Reporting guidelines for study protocols recommend description



of how missing data will be handled



SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

An-Wen Chan, ¹ Jennifer M Tetzlaff, ² Peter C Gøtzsche, ³ Douglas G Altman, ⁴ Howard Mann, ⁵ Jesse A Berlin, ⁶ Kay Dickersin, ⁷ Asbjørn Hróbjartsson, ³ Kenneth F Schulz, ⁸ Wendy R Parulekar, ⁹ Karmela Krleža-Jeric, ¹⁰ Andreas Laupacis, ¹¹ David Moher²¹⁰

Guideline	Item 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	
SPIRIT (BMJ. 2013;346:e7586.)		
SPIRIT-PRO (JAMA. 2018;319(5):483494)	20c State how missing data will be described and outline the methods for handling missing items or entire assessments (eg, approach to imputation and sensitivity analyses).	



SPIRIT-AI (BMJ 2020;370:m3210)	20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)
SPENT 2019 (BMJ 2020;368:m122)	20c Statistical methods to handle missing data (eg, imputation). In addition for series: Definition of analysis population relating to protocol nonadherence (eg, as-randomised analysis).

The SAP guideline for RCTs recommends it



Clinical Review & Education

JAMA | Special Communication

JAMA. 2017;318(23):2337-2343. doi:10.1001/jama.2017.18556

Guidelines for the Content of Statistical Analysis Plans in Clinical Trials

Carrol Gamble, PhD; Ashma Krishan, BSc; Deborah Stocken, PhD; Steff Lewis, PhD; Edmund Juszczak, MSc; Caroline Doré, BSc; Paula R. Williamson, PhD; Douglas G. Altman, DSc; Alan Montgomery, PhD; Pilar Lim, PhD; Jesse Berlin, ScD; Stephen Senn, PhD; Simon Day, PhD; Yolanda Barbachano, PhD; Elizabeth Loder, MD, MPH

Item 28: Missing Data



Reporting and assumptions/statistical methods to handle missing data (eg, multiple imputation)





Assets of Internal Medicine

CONSORT 2010 Statement Diplated Guidelines for Reporting Parallel Group Randomized Trials

based of these files alone begins to those the new band below that the law to be followed begins

many and support to regard the supplier of contrasts, or contrasts of the supplier of the supp

later for it rate t

man and Today, No said

Rand

The second second second second second second

BMI

RESEARCH METHODS & REPORTING

infrastructure de las meditales randomised t of test of tests and

No let 4 days may 2 to opport 1 to 40 Reading Test may have been 8 to Wa to mile. In Audior want specifical and to be been for the reporting of latest Worse & Supplied and

make of the pressure in INCOME OF CONFIDER Station In 19 least dead

Section . -Committee of pages

4-4-

Reporting of Patient-Reported Outcomes in Randomized Trials

The CONSORT PRO Extension

Sugar C. Miller, Tol.

halafron's maleston'

> Demokratic Spring Springs Spinister Fernand of Fallow Reported the

All discounts in the

RESEARCH METHODS & REPORTING

Improving the reporting of progressic trials; an extension of the CONVIORT statement

Service Services "Tital Search and September Stocks of Section "Sections" Andread Tomas Traditions I Technic Straff prompted Teach Institute of April Speci-Progress had an independent religion between the had progress and religion. the college. To differed and harder groups to the modification in the little of garded trisk-roots over the pot-littly information

The second secon

Assets of Arbertal Medicine

Academic and Chesc

Reporting Randomized, Controlled Triph of Revisal Internections. An Elaborated CONCORT Statement

or larger to the large time the first halo are all other transfers. We want to be defined the of

Control of the Control Reporting of Noninferiority and Equivalence Randomized Trials

44.00

Extension of the CONSORT 2010 Statement City Program Political Street Political Control of Cont

the Bears has a side of a

CONSORT for Reporting Randomized Controlled To International Conference Abstracts: Explanation and Elaboration

Acceptant some Cigoria

Annals of Internal Medicine Methods and Processes of the CONCORT Group Example of an

Extension for Trials Assessing Monoharmacologic Treatments and there are the contrasts for improve them in constitute the first and they have the first substitute of ω

THE RESIDENCE OF STREET

remain introduction to the later many

Resident The Committee of the Co you gother solvers of the strips, and in these law Control of the second s

Programming Common year a left-room of

-

Section 19, special and the state of the sta

the first and the color of the mention in which give experience to the large of the larg

Committee of the commit

THE PARTY NAMED IN COLUMN

provides the provides of the control the description or other and date in a first

Rose the layered with year as the last mild appeal in the little or makes of the control of the last to the last to the mild of the last to the last to the last mild of the last to the last to the last mild of the last to the last to the last mild of the last to the last to the last mild of the last to the last mild of the last to the last to the last to the last to the mild of the last to the last to the last to the last to the mild of the last to the last to the last to the last to the mild of the last to the last to the last to the last to the mild of the last to the last to the last to the last to the mild of the last to the mild of the last to the mild of the last to the mild of the last to the last

No mode, by Collection Leading to Analysis makes transport of any place public forms the Sorbard, police (1994 BT accords (7) desired Translation

HE STAND SHOWER TO Control of the late of The CORNER Considered Residues of Agenting States Statement which, you have not become training and being a first state of the States of the S Pillman automorphist Laborate and in

and of the COROCK Coronic Coronic Coro

HOUSE Federate has been been and the second of the second and regardance traps. Mr. Science Street Science Science (R) and mechanism: In the course serving new

program from a first board to serverine by one patients the contract of the one books for new or

stable above a personne

a des desident in an

AND ADDRESS OF THE PARTY OF THE the statement

mythic set make if

Principle common transferration reposits to an in-tipero it is excellent. The most It never used to be explicitly stated in the CONSORT <u>i escai cilisti o esica</u>

Statement and its extensions



CONSORT 2025 statement: updated guideline for reporting randomised trials





Solly Hopmaril", An-Wim-Chon, Gary S Callins, Adhiem Holbjortsson, Donid Müher, Kenneth F Schole, Both Tunn, Bakesh Agganard Michael Berkwitt, Jesse A Berlin, Nite Bhundari, Nancy J Butcher, Manor K Compbell, Buncie C W Chideler, Diana Elbourne, Andrew Farmer. Dean A Fergusson, Robert M Golob, Steven N Goodman, Tamerry C Hoffmann, John P A Isannidis, Brannan C Eshan, Bachef L Enowles, Sorah II Lamb, Stoff Emin, Ellesbeth Loder, Martin Offringa, Philippe Ravaud, Dawin P Richards, Ficark W Rockhold, David I. Schriger, Mondi E. Segfrind, Sophie Staniszewska, Rad S Taylor, Lehono Thabane, David Targerson, Sunsta Volna, Ian R Wille, Inabelle Boutson



Well designed and properly executed randomised trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the quality of reporting is not optimal. The CONSORT (Consolidated Standards of Reporting Trials) statement was designed to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomised trial. CONSORT was first published in 1996, then updated in 2001 and 2010. Here, we present the updated CONSORT 2025 statement, which aims to account for recent methodological advancements and feedback from end users. We conducted a scoping review of the literature and developed a project-specific database of empirical and theoretical evidence related to CONSORT, to generate a list of potential changes to the checklist. The list was enriched with recommendations provided by the lead authors of existing CONSORT extensions (Harms, Outcomes, Non-pharmacological Treatment), other related reporting guidelines (TIDieR) and recommendations from other sources (eg. personal communications). The list of potential changes to the checklist was assessed in a large, international, online, three-round Delphi survey involving 317 participants and discussed at a two-day online expert consensus meeting of 30 invited international experts. We have made substantive changes to the CONSORT checklist. We added seven new checklist items, revised three items. deleted one item, and integrated several items from key CONSORT extensions. We also restructured the CONSORT checklist, with a new section on open science. The CONSORT 2025 statement consists of a 30-item checklist of essential items that should be included when reporting the results of a randomised trial and a diagram for documenting the flow of participants through the trial. To facilitate implementation of CONSORT 2025, we have also developed an expanded version of the CONSORT 2025 checklist, with bullet points eliciting critical elements of each item. Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomised trials to ensure that trial reports are clear and transparent.

April 14, 312% https://doi.org/10.1016/ 50149-6756/2500623-6 Oxfood Clinical Trials flenearch Unit, Centre for Statistics in Medicine, University of Oxford: (Prof S Ropesell (Phil.) ETurn DPNE; Department of Mindicine, Women's College Research Institute, University of Tanantia, Tanantia, GNL (Prof A.W.Chan MD DPW), MK EQUATOR Carrow, Contractor Statistics in Medicine, University of Oxford, Oxford, UK (Prof.C.S.Colline Philis Dentire) for Evidence Based Wedicine Odense and Cookspre Denmark, Department of Clinical Research, December of Southern Demmark. Odema Denmark (Ford & Hothigetown Philly Open

	Number	CONSORT 2025 checklist item description
(Continued from previous)	page)	
Randomisation		
Sequence generation	17a	Who generated the random allocation sequence and the method used
	17b	Type of randomisation and details of any restriction (eg. stratification, blocking and block size)
Allocation concealment mechanism	18	Mechanism used to implement the random allocation sequence (eg. central computer/telephone; sequentially numbered, opaque, sealed containers), describing any steps to conceal the sequence until interventions were assigned
Implementation	19	Whether the personnel who enrolled and those who assigned participants to the interventions had access to the random allocation sequence
Blinding	20a	Who was blinded after assignment to interventions (eg. participants, care providers, outcome assessors, data analysts)
	20b	If blinded, how blinding was achieved and description of the similarity of interventions
Statistical methods	21a	Statistical methods used to compare groups for primary and secondary outcomes, including harms
	21b	Definition of who is included in each analysis (eg. all randomised participants), and in which group
	21c	How missing data were handled in the analysis
	21d	Methods for any additional analyses (eg. subgroup and sensitivity analyses), distinguishing prespecified from post hoc



Not it is! Fresh from the press today! research.stjoes.ca

SPIRIT

Enhancing the transparency and reporting of randomised trials: update of the SPIRIT 2013 and CONSORT 2010 Statements

Virtual consensus meeting • 1st - 2nd March 2023





Update on CONSORT 2025 FYI

- □ New CONSORT 2025 Update
 - ✓ BMJ: www.bmj.com/content/389/bmj-2024-081123
 - ✓ Lancet: www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00672-5/abstract
 - ✓ JAMA: https://jamanetwork.com/journals/jama/fullarticle/2832868
 - ✓ Nature Medicine: www.nature.com/articles/s41591-025-03635-5
 - ✓ PLoS Medicine: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004587
- □ New CONSORT 2025 E&E
 - ✓ BMJ E&E: https://www.bmj.com/content/389/bmj-2024-081124



- □ BMJ has also published several editorials highlighting the importance of CONSORT (and Doug Altman's legacy and pivotal role) and reporting guidelines more generally:
 - √ https://www.bmj.com/content/389/bmj.r734
 - √ https://www.bmj.com/content/389/bmj.r718
 ✓ https://www.bmj.com/content/389/bmj.r718
 ✓ https://www.bmj.com/content/389/bmj.r494
- □ New CONSORT/SPIRIT 2025 Website
 - √ www.consort-spirit.org

Update on SPIRIT 2025 FYI

- □ New SPIRIT 2025 Update
 - ✓ BMJ: https://doi.org/10.1136/bmj-2024-081477

- ✓ JAMA: https://doi.org/10.1001/jama.2025.4486
- ✓ Lancet: https://doi.org/10.1016/S0140-6736(25)00770-6
- ✓ PLOS Med: https://doi.org/10.1371/journal.pmed.1004589
- ✓ Nature Med: https://doi.org/10.1038/s41591-025-03668-w
- ☐ New SPIRIT 2025 E&E
 - ✓ BMJ E&E: https://doi.org/10.1136/bmj-2024-081660
- □ New CONSORT/SPIRIT 2025 Website
 - √ www.consort-spirit.org



But, it is expected that if planned in the SAP or protocol, then the results



on handling of missing data will be reported



Regulatory agencies have provided guidance on how address it in



regulatory studies





The Prevention and Treatment of Missing Data in Clinical Trials: An FDA Perspective on the Importance of Dealing With It

RT O'Neill¹ and R Temple²

The

In



2 July 2010 EMA/CPMP/EWP/1776/99 Rev. 1 Committee for Medicinal Products for Human Use (CHMP)

Guideline on Missing Data in Confirmatory Clinical Trials

Discussion in the Efficacy Working Party	June 1999/
	No vem ber 2000
Transmission to CPMP	January 2001
Released for consultation	January 2001
Deadline for Comments	April 2001
Discussion in the Efficacy Working Party	October 2001
Transmission to CPMP	No vem ber 2001
Adoption by CPMP	No vem ber 2001
Draft Rev. 1 Agreed by Efficacy Working Party	April 2009
Adoption by CHMP for release for consultation	23 April 2009
End of consultation (deadline for comments)	31 October 2005
Rev. 1 Agreed by Efficacy Working Party	April 2010
Adoption by CHMP	24 June 2010
Date for coming into effect	1 January 2011

This guideline replaces Points to Consider on Missing Data in Clinical Trials (CPMP/EWP/1276/99).

Key words

Baseline Observation Carried Forward (BOCF), Generalised Estimating Equations (GEE), Last observation carried forward (LOCF), Missing at random (MARA), Missing completely at random (MCAR), Missing Data, Mixed Models for

September 1998 CPMP/ICH/363/96

ICH Topic E 9 Statistical Principles for Clinical Trials

Step 5

NOTE FOR GUIDANCE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS (CPMP/ICH/363/96)

TRANSMISSION TO CPMP	February 1997
RELEASE FOR CONSULTATION	February 1997
COMMENTS REQUESTED BEFORE	June 1997
FINAL APPROVAL BY CPMP	March 1998
DATE FOR COMING INTO OPERATION	September 1998

The Records In

ch.stjoes.ca

Other major methodology groups have set standards of



how to deal with it



PCORI METHODOLOGY REPORT

October 2021

© 2021 Patient-Centered Outcomes Research Institute. All Rights Reserved.

The Methodology Standards were updated in February 2019 and are available at www.pcori.org/methodology-standards.



PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE

4: STANDARDS FOR PREVENTING AND HANDLING MISSING DATA

MD-1: Describe methods to prevent and monitor missing data. Investigators should explicitly state potential reasons that study data may be missing. Missing data can occur from patient.

dropout, nonresponse, data collection problems, incomplete data sources, and/or administrative issues. As relevant, the protocol should include the anticipated amount of and reasons for missing data, plans to prevent missing data, and plans to follow up with study participants. The study protocol should contain a section that addresses steps taken in study design and conduct to monitor and limit the impact of missing data. This standard applies to all study designs for any type of research question.

MD-2: the valid statistical methods to deal with missing data that properly account for statistical uncertainty owing to missingness.

Valid statistical methods for handling missing data should be prespecified in study protocols. The analysis should explore the reasons for missing data and assets the plausibility of the assumptions associated with the statistical methods. The potential impact of missing data on the results and limitations of the approaches used to handle the missing data should be discussed.

Estimates of treatment effects or measures of association should be based on statistical inference procedures that account for statistical uncertainty attributable to missing data. Methods used for imputing missing data should produce valid confidence intervals and permit unbiased inferences based on statistical hypothesis tests. Bayesian methods, multiple imputation, and various likelihood-based methods are valid statistical methods for dealing with missing data. Single imputation methods, such as last observation carried forward, baseline observation carried forward, and mean value imputation, are discouraged as the primary approach for handling missing data in the analysis. If single imputation-based methods are used, investigators must provide a compelling scientific rationale for why the method is appropriate. This standard applies to all study designs for any type of research question.

MD-3: Record and report all reasons for dropout and missing data, and account for all patients in reports.

Whenever a participant drops out of a research study, the investigator should document the following: (1) the specific reason for dropout, in as much detail as possible. (2) who decided that the participant would drop out; and (3) whether the dropout involves participation in all or only some study activities, investigators should attempt to continue to collect information on key outcomes for participants unless consent is withdrawn. All participants included in the study should be accounted for in study reports, regardless of whether they are included in the analyses. Any planned reasons for excluding participants from analyses should be described and justified. In addition, missing data owing to other mechanisms (e.g., nonresponse and data entry/collection) should be documented and addressed in the analyses.

MD-4: Examine sensitivity of inferences to missing data methods and assumptions, and incorporate it into the interpretation.

Examining sensitivity to the assumptions about the missing data mechanism (i.e., sensitivity analysis) should be a mandatory component of the study protocol, analysis, and reporting. This standard applies to all study designs for any type of research question. Statistical summaries should be used to describe missing data in studies, including a comparison of baseline characteristics of units (e.g., patients, questions, clinics) with and without missing data. These quantitative results should be incorporated into the interpretation of the study and reflected in the discussion section and, when possible, the abstract of any reports.

Rationale for These Standards

These standards apply to both missing data and inaccurate data (e.g., in electronic health records), the treatment of which are governed by similar design and analytical considerations (Senchimo) et al. 2015). Missing data are unrecorded or inaccurate values or unavailable information that would be meaningful for data analysis and could affect results and conclusions. Possible reasons for missing data include the following:

- Recoding or measurement errors
- Utilizing data sets derived from records not intended for research, such as those generated from routine clinical care
- Involving or evaluating participant populations that are harder to retain over time, making it difficult to collect data





What is the <u>current</u> <u>practice</u>?

Unfortunately, the practice is



not good!


Many reviews show that the practice is far from optimal.





And the latest reviews show that nothing has changed





☐ The practice is <u>variable</u>

□ The least optimal methods are <u>frequently used</u>
 □ The most appropriate methods are <u>infrequently used</u>
 □ Regardless of whether or not the design is a randomized or non-randomized, the handling of

missing data in longitudinal studies is inadequate



What are the <u>best</u> imputation methods?

It depends!



On What?

The choice of methods depends on the



assumptions about the pattern of missingness



Different patterns of missing data

Missing completely at random (MCAR)

 The likelihood of missing data is unrelated to any observed or unobserved variables.

Missing at random (MAR)

 The likelihood of missing data is related to observed variables but not to unobserved variables

Not missing at random (NMAR)

The likelihood of missing data depends on the unobserved data

Madison Zhang Former PhD HRM Student







Journal of Clinical Epidemiology 98 (2017) 67-80

Journal of Clinical Epidemiology

A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials

Yuqing Zhang and Akram Alyass. Thuva Vanniyasingam. Behnam Sadeghirad.

Iván D. Flórez and Sathish Chandra Pichika. Sean Alexander Kennedy. Ulviya Abdulkarimova. Yuan Zhang. Tzvia Iljon. Gian Paolo Morgano. Luis E. Colunga Lozano. Fazila Abu Bakar Aloweni. Luciane C. Lopes. Juan José Yepes-Nuñez and Yutong Fei. Li Wang. Lara A. Kahale. David Meyre. Elie A. Akl., Lehana Thabane. Gordon H. Guyatt.

Consider using multiple imputation or mixed model methods—they have been shown were superior to other methods in terms of overall performance and bias,
 Avoid LOCF approach
 Perform sensitivity analysis to assess robustness

What is performance based on?

STATISTICS IN MEDICINE

Statist. Med. 2006; 25:4279-4292

Published online 31 August 2006 in Wiley InterScience (www.interscience.wiley.com) DOI: 10.1002/sim.2673



The design of simulation studies in medical statistics

Andrea Burton 1,2,4,7, Douglas G. Altman 1, Patrick Royston 1,3 and Roger L. Holder 4

¹Cancer Research UK/NHS Centre for Statistics in Medicine, Oxford, UK.

²Cancer Research UK Clinical Teials Unit, University of Birmingham, Birmingham, UK.

³MRC Clinical Trials Unit, London, UK.

⁴Department of Primary Case and General Practice, University of Berningham, Berningham, U.K.

Bias: deviation from the truth (ie. Specified effect value)

Accuracy: mean square error (MSE), which incorporates both bias and variability of the effect

Coverage: the proportion of times that the obtained confidence interval contains the true specified effect value

Empirical Type I error rate: the proportion of simulation samples in which the null hypothesis of no effect is rejected at the nominal, usually 5 per cent, significance level, when the null hypothesis is false

Empirical type II error rate: the proportion of *p*-values from testing the null hypothesis of no difference on each simulated sample that are less than the nominal 5 per cent significance level, when the null hypothesis is true


Empirical Power: 1- Type II error rate

<u>Important</u>

Please note that <u>ignoring missing</u> data is essentially another way of handling missing data which



assumes that they are <u>missing</u> completely at random





- ☐ The choice of method is dependent on assumptions on pattern of missingness
- ☐ In general,
 - ✓ single imputation methods such LOCF, mean imputation, worst/best case scenarios, don't perform well
 - ✓ MI or model-based imputation methods perform better



What imputation <u>cannot</u> do

Imputed data cannot...

De used as replacement for better design and conduct of trials to prevent missing data!



- □<u>tell why</u> data were missing!
- Itell whether or not the imputed value is true
- be used as clinical decisions for individual patients with missing data!



I tell colleagues that the best approach to missing data is to PREVENT IT!



Published in final edited form as:

Ann Intern Med. 2011 January 18; 154(2): 113-117. doi:10.1059/0003-4819-154-2-201101180-00010.

Addressing Missing Data in Clinical Trials

Thomas R. Fleming, PhD University of Washington, Seattle, Washington



Tom Fleming



"The preferred and often only satisfactory approach to addressing missing data is to prevent it" Strategies for preventing attrition

(DeMauro SE. Does Attrition Still Matter And How Can It Be Reduced? Hot Topics in Neonatology. Washington DC, 2022)

- Engage families in the design of your study
- Employ peer navigators to support study participants
- ✓ <u>Help families travel</u> or travel to the family/school
- ✓ Have flexible hours and scheduling
- ✓ Provide childcare for siblings
- Develop and use <u>remote/virtual</u>
 <u>assessments</u>
- ✓ Make the <u>assessments relevant</u> (ie patient centered)



Keep in touch, remind them that their contributions are valued

Sara B. DeMauro, MD, MSCE, is an Associate Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine

There is some hope that decentralizing clinical



trials will also reduce the likelihood of missing data!

My advice: Use practical commonsense measures

Work with mentors who are experienced in running trials or

Collaborate with a biostatistician or methodologist

<u>Invest in hiring qualified research staff</u> (<u>research coordinator</u>)

<u>Communicate with and educate patients</u> about the trial/study and importance of complete data for study integrity







Set targets for missing data and devise strategies if not Allocate meeburces to effective data collection, and following up patients for

<u>Design a simple, easy-</u> <u>toimplement protocol</u> with objectives in mind, with lots of flexibility to minimize attrition





<u>Plan sensitivity analyses</u> to assess the impact of missingness on key findings using best methods depending on the nature of

missingness



Follow proper reporting guidance on

what and how to report



There is another rare, but generally unrecognized



problem that can lead to missing data in trials

Patients requesting withdrawal of their already collected data at the time when they withdraw from a study





Contents lists available at ScienceDirect

Contemporary Clinical Trials

journal homepage: www.elsevier.com/locate/conclintrial



Editorial letter

Data withdrawal in randomized controlled trials: Defining the problem and proposing solutions A commentary

Chenglin Ye a,d,e, Lora Giangregorio b, Anne Holbrook c,d,f, Eleanor Pullenayegum d,e,f, Charlie H. Goldsmith d,e,f, Lehana Thabane d,e,f,g,*

- a Department of Mathematics and Statistics, McMaster University, Hamilton, Ontario, Canada
- b Department of Kinesiology, University of Waterloo, Waterloo, Ontario, Canada
- ^c Division of Clinical Pharmacology & Therapeutics, Department of Medicine, McMaster University, Canada
- ^d Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
- * Biostatistics Unit, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
- The Centre for Evaluation of Medicines, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
- * Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada

Data withdrawal is addressed in **Chapter 3: Consent Process; Article 3.7B:** "Participants in such research must have the opportunity to refuse consent and request the withdrawal of their data and/or human biological materials whenever possible, practicable and appropriate (Article 3.1)."



Tri-Council Policy Statement

Ethical Conduct for Research Involving Humans

TCPS2 2018

Canadian Institutes of Health Research
Natural Sciences and Engineering Research Council of Canada
Social Sciences and Humanities Research Council



Government of Canada

Gouvernement du Canada



However,....

"REBs must also consider whether the option to withdraw data is appropriate. In some types of research, permitting the withdrawal of data and/or human biological materials could skew the results of the research, invalidating the study and denying potential benefits to society. The

invalidation of study findings may also <u>demonstrate a lack of</u> respect for the contributions made by other <u>participants</u>"

What are the frequently asked questions



about missing data?

☐ How small a % of missing data to make it ignorable?

✓ It depends!



- ✓ On size of study, reasons for missing, pattern of missingness
 - ☐ How large a % of missing to make it worthless to impute?
- ✓ Evidence suggests that even upto 90% of missing outcome data is worth imputing
- ☐ What if I have missing demographic or prognostic information instead of outcome data? Will the same methods work?



- ✓ This is unresolved
- ✓ No reason to suspect that the methods won't work
- ☐ For large trials, is it really worth worrying about missing data?
 - ✓ Yes, it's worth planning for regardless of the size of a study
- ☐ I don't like to work with "fake" data in my study?



- ✓ You are essentially <u>assuming data are missing completely at</u> <u>random</u>
- ✓ This has been shown to be a <u>biased</u> strategy □Can I do posthoc imputation analysis?
- ✓ Yes, but not ideal!
- ✓ It is best to plan for this as part of your design protocol
- □What software can I use to perform imputation?



- ✓ Most statistical software have MI algorithms
- □What if I don't know how to do MI imputation?
 - √ Get help
 - ✓ Best to collaborate with a biostatistician from start
- ☐ Can I assess the MAR assumption?
 - ✓ This MAR assumption is not verifiable, because it assumes that missing data are dependent on missing data—which you don't have.



- What about comparing the baseline characteristics of those with and without missing data to assess the MAR assumption?
 - ✓ The comparability of baseline characteristics won't tell you anything about the comparability of missing and available outcomes
 - ✓ So, this is not a viable option for assessing MAR assumption □ What about missing data on secondary and tertiary outcomes?
 - ✓ The same issues apply to all outcomes regardless of whether they are primary, secondary or tertiary
- ☐ Is there anything else I can consider?
 - ✓ Yes, consider using time-to-event as an outcome



- ✓ Missing outcomes are censored at the last observation, and therefore corresponding
 patients are still included in the analysis without the need to impute
- ☐ What about patients who died, and therefore are missing secondary outcomes after dying?
 - ✓ Such outcome data are considered missing by design, and therefore not imputed

What are the available resources for dealing with missing data?



YALE JOURNAL OF BIOLOGY AND MEDICINE 86 (2013), pp.343-358. Copyright © 2013.

FOCUS: RESEARCH AND CLINICAL ETHICS

Strategies for Dealing with Missing Data in Clinical Trials: From Design to Analysis



James D. Dziura^{a,c*}, Lori A. Post^a, Qing Zhao^{b,c}, Zhixuan Fu^{b,c}, and Peter Peduzzi^{b,c}

The NEW ENGLAND JOURNAL of MEDICINE

SPECIAL REPORT

The Prevention and Treatment of Missing Data in Clinical Trials

Roderick J. Little, Ph.D., Ralph D'Agostino, Ph.D., Michael L. Cohen, Ph.D., Kay Dickersin, Ph.D., Scott S. Emerson, M.D., Ph.D., John T. Farrar, M.D., Ph.D., Constantine Frangakis, Ph.D., Joseph W. Hogan, Sc.D., Geert Molenberghs, Ph.D., Susan A. Murphy, Ph.D., James D. Neaton, Ph.D., Andrea Rotnitzky, Ph.D., Daniel Scharfstein, Sc.D., Weichung J. Shih, Ph.D., Jay P. Siegel, M.D., and Hal Stern, Ph.D.







Canadian Journal of Cardiology 37 (2021) 1322-1331

Review

Missing Data in Clinical Research: A Tutorial on Multiple Imputation

Peter C. Austin, PhD, a.b.e. Ian R. White, PhD, Douglas S. Lee, MD PhD, a.b.e.f and

Stef van Buuren, PhDgsh

CMAJ

Analysis

Randomized trials with missing outcome data: how to analyze and what to report

Rolf H.H. Groenwold MD PhD, Karel G.M. Moons PhD, Jan P. Vandenbroucke MD PhD

he gold-standard study design to evaluate the effects of medical treatment is the randomized trial. Assignment to treatment groups is a random process, and baseline differences in prognostic factors are due to chance. Consequently, at baseline, both groups are expected to be statistically comparable with

comes were handled in the analysis, and participants with missing outcomes are typically omitted from the analysis. This results in a "complete case intention-to-treat analysis."

An example of bias due to missing

Competing interests: None declated.

This article has been peer servicesed.

Correspondence to: Rolf Georgewold r.h.h.groenwold @umcutrocht.nl

The Recoard In





Journal of Clinical Epidemiology

Journal of Clinical Epidemiology 134 (2021) 79-88

ORIGINAL ARTICLE

Framework for the treatment and reporting of missing data in observational studies: The Treatment And Reporting of Missing data in Observational Studies framework

Katherine J. Lee^{a,b,*}, Kate M. Tilling^c, Rosie P. Cornish^c, Roderick J.A. Little^d, Melanie L. Bell^e, Els Goetghebeur^f, Joseph W. Hogan^g, James R. Carpenter^b, on behalf of the STRATOS initiative

"This framework seeks to support researchers in thinking systematically about missing data and transparently reporting the potential effect on the study results, therefore increasing the confidence in and reproducibility of research findings".



Missing Outcome Data in Recent Perinatal and Neonatal Clinical Trials

Surser S, 750, MARS¹⁷⁷ Regar Lis, MSc.* Jopp Phang, MSc.* Sare S, SeMeurs, MS, MSC.** (rong Mang, MSc.* Learning Mosagnes, MS, 760, ¹⁸⁶7) Barbara Schmidt, MS, MSc.¹⁷ Revent Kryslani, SM, MSc.** Settors Thalese, 750⁽⁶⁾

Missing outcome data in descal trials may separate the validity of the trial retults and inferences for clinical practice. Although side and proterm newborns are treated as a captive patient population during their stay in the NICIs, their longterm outcomes are often assertained after discharge. This greatly increases the risk of attrition. We surveyed recessly published perioatal and necessal randomited trials in 7 high-impact general medical and pediatric journals to review the handling of missing primary outcome data and any choice of imputation methods. Of 87 eligible totals in this survey, 77 (89%) had incomplete primary outcome data. The missing extrome data were not discussed at all in 9 reports (12%). Most study teams restricted their main analysis to participants with complete information for the primary outcome (61 trials; 79%). Only 38 of the 77 teams (49%) performed sensitivity analyses using a variety of imputation methods. We conclude that the handling of missing primary outcome data was frequently inadequate in recent randomized perinatal and measural trials. To improve future approaches to missing extrorre data, we discuss the strengths and limitations of different impatation methods, the appropriate estimation of sample size, and how to deal with data withdrawial However, the best strategy to reduce bias from mining outcome data in perinatal and monatal trials remains prevention, investigators should antidpate and preempt missing data through careful study design, and closely monitor all incoming primary outcome data for completeness during the conduct of the

Missing switcome data in modoralized controlled trials (RCTs) may propordize the comparability between the comparison groups and companions information about treatment effects. Missing data may arise in many ways in portional and neomatal trials in the birth heapital or RCCs, parents or guardians of participating infants may not respond to questions, tall to adhere to trial protocols, request withdrawed from pertocols early, or refuse congoing data collection. Although carregivers can easily assens in-hospital encourse for sick and present newborn infants admitted to the ICDs, their important longer-form outcomes require assertationers later in childhood and increase the risk of attrition. For example, nearly 40% of the primary sustance data were relating at a gar 5 years in a recent high-peofile trial occupacing general anesthesia with awake regional anesthesia for infants undergoing levels a resident of the controlled of the protocol of the p

Despite the large literature on prevention and handling of mining data, hit reporting and desling with mining data remain inadequate in chinical trials. We in plausitist that perinatel and mountail trials are not exceptions. We surveyed recently published perinatel and secondal RCTs in high-impact general moderal and pediatric journals to review the handling of mining primary outsine data and use of impactation methods, we despite the perinate and restriction of different impactation methods, and

Satract



Torse to Direct (internally engineerings and Suffer Specification disproprie Deley, D. Josephili Intelligent Sensites (Species Sinterly Sensity States) Afficial analysis of Charles Statement & Charles & Charl Described of Religious Physics School of Bridge Interior of Workshopen, Philadelinia, Remaining Separate of Palatine Sampley Scientification Consent Record & CopingStery (Note: Sentence and Record provinced of cought from an installability Throughouts Propietros attaligator Canorina Springers Distores Grants Cierce for Concigonal of that Warking & more Novel districtments brivel fathering. Destinations, Thereign of Despertusings and Section 1. Department of Golde Health, Districtional Disserving Days Book Stade officer Trimerban Professor Postation of specials Panagarong Windpicks, N. Smirtle Pottoson Robbins shakketir (merculy figration) Intelligence on Town to Automotive interesting light free

This is not likely exhibits by outside Jung summerly and designed this memority, explored 300, 1911 admirated support, explored the memoring and dense the public wile colonity, the foreign by Mayane, and arthresides suggest, make multiple official residence, arthresides suggest, make multiple official residence, the memoritance of above dense and antiferror explored the medication of above dense and explored distribute and performance suggest, our man explored substitute females in the exploration, and all and two substitute females in the exploration, and all and two substitutes for the first exploration and and the substitute of the first exploration and and the substitute of the first explored and antiferror explored the medication of the exploration and and the substitute for the first exploration and and the substitute of the medication and the substitute of the substitute of the medication and the substitute of the substitute of the medication and the substitute of the substitute o

Microsoftware 14 percent of the

Accessed for supplication than 5, 2007.

Approxis germanisms to grade Trabure (m) Signamust of least Science Methods, Science, and Impail, Wallader Cranning, John San Stullace Seconds Science, M. Science Science Science (M) Sid Startist Am Land Laminton, Ot Science (M) All Land Stullage (M)

ROUNCE COR NAMED FOR BUY AND DOCUMENTS

Douglas G. St. St. Street, Brownian Assessment Companies.

PERSONAL PROPERTY AND PARTY.

CONTROL OF THE PARTY IN CONTROL TO A CONTROL THE

Speller (14, 16.5 Parry Cets) Warry Sytume Sale in Search Fernatol and Secretal Directs Trans Federica 2004 (SUD +00000010)

Making the Most of Missing Data

Four Stource, Mt. MAS? and Sactor! S. Dreenberg, MS. MS. MASS.

Cinical trials are demanding, resource immunion, and ensemble to the health and well-being of children. In this issue of features, Li and collapsace* notine the magnitude of an other-overbooked problem within mounted and perinatal clinical trials. Their results demonstrate that missing primary nations data are often ignored or minhamilial, which deverouse statistical power, increases that, and may proportion the validity of clinical trial results. The authors previde percrical approaches to result mining variance data through clinical trial design strategies and revines according an analysis and perinatal people of the mining data is not unique to the normal and perinatal peopletism, and is isomorm in trials festived on pediatric clonical medical conditions, including SIT,* obscity,** and sethers.** Thus, the concepts reviewed by Li and relineages apple brandle.

Although clinical trials in pollistic populations are challenging trials in the second and ports atal population contend with eithical and practical considerations that make studying this reincrable population increasingly difficult. "With sick and praters inducts sortions benefit abundants at higher rates." there is intrusing effect from discuss or researchers, clinicians, and families to standardine and prioritian the most miscusingful autoence. (In III Many of these critical autoence centre on long term quality of his and sour-adorevingment, which may not be deserted until until into childhoust and have life-ing implications. These important summers a six trained yours after heapful dischange greatly increase the potential of the initial policy.

Lit and colleagues methos been efficient researchers and discident should be expetation of the potential for mining outcome data and take super to relating this rela-These efficient most man during the design stages before the clinical trial begins, when relatinishes should be treeded early to consider how attestion may affect sample size considerations and to identify sensitivity analyses best valued for the relatinishes as a sensitive as massive as alternative standardings, makes a deconsileated dispositive of a conference on massive as alternative standardings, makes a deconsileated dispositive of a conference on participant families. Decisionalized clinical trials are technology, home health providers, and local clinics in data softening to residue gaugaphic, thus, and travel related families for participant families and may improve participant technology. Direct to-density trials are similar, but also forter the role of powers and carrigions in suggesting clinical research activities. During the trial, it is november of researchers to reagap porticipates and their femilies, whereas minintagin lawders and manintagin trial-related benefits. After the total, disating results with families beign maintain the relation to the only expense or without for incidence that the trial.

Superiting guidelines, each as the Consolidated Standards of Reporting Tradachtement, may benefit from indesting mining natures: data reporting standards. ¹⁸ Wedshird journals should liveat as port of the review process that mining standards data he reported and that heat practice sensitivity analyses are used to inform the suscerulary that results from mining data. Checiaus must be excelled to the from a first standard of the standard of the standard trade and incorporating knowledge guised flows such trade into discuss parties. Heaven, it is receivanty to take a numeral view toward mining data. Indeed, some disciplinal looper or discipling processing to the ansatz of the standard parties. Consistent of February, Edit (Inventor) Selector's debter Select Separature S. Separature of Research Select Select Select Select Select Select Select Selection and Select S

In liquities and directing makes the controllery and thereign is enturely for important industrial amount, and such software page and the flag managering as industrial and agree to be associated to all controllers of the many

Annual transport of the Annual States of the Annual

Acres companies in level 1 treating 40, 401. Not treat shares rather \$1500 treating only. Sorter \$1.000 treating promption on

DANCE CON ELection Print, MC 400, Co.

Somethia.

Name to other factor

makes a recent makes in the terming to broke appet that makes for recent, errors. This little application with a release.

SMITH IN PARK & conserved to this other solver bank arrive of executable conjugates to the area, and do to

Budle Claimant, Greening St. Many he Manuscriptors, Reams 200, 15th electrode


COMMENTARY


The Recoardh In


PRINTED VALUE ISS. NAME IS NAME TO SET AND SET


There are many textbooks on the topic















Please share your favorite resources for everyone to learn from





- Think about the possibility of missing data during the design and use approaches to minimize or prevent it
 - ✓ Build this into the protocol
 - ✓ Build some <u>sensitivity analysis</u> into the protocol to assess robustness

Imputation can increase the <u>efficiency and validity</u> of the
analyses
Note that not all imputation methods work the same way—
some are more efficient and less biased than others
For most trials, <u>ignoring missing data</u> is not a viable
option

So, what if I have some missing data or patients in my clinical trial: what's the big deal, and wouldn't imputation solve the problem?

- ✓ Big deal because of the implications on inference
- ✓ Best option is to <u>prevent missing data</u>



- ✓ Imputation is <u>not a panacea</u>, but can help as 2nd best option
- ✓ Imputation <u>should not</u> be used as substitute for good design and planning

